{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:51:22Z","timestamp":1791571882151,"version":"4.3.4"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01038-3","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:21:09Z","timestamp":1791523269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paraneoplastic Intracellular Neuropathies: A Narrative Review"],"prefix":"10.1007","author":[{"given":"Giovanni","family":"Siconolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Mathews","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ausilia","family":"Sciarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-505X","authenticated-orcid":false,"given":"Marco","family":"Luigetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"8","key":"1038_CR1","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","volume":"75","author":"F Graus","year":"2004","unstructured":"Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135\u201340. https:\/\/doi.org\/10.1136\/jnnp.2003.034447.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u20132","key":"1038_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jneuroim.2005.03.020","volume":"165","author":"F Graus","year":"2005","unstructured":"Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol. 2005;165(1\u20132):166\u201371. https:\/\/doi.org\/10.1016\/j.jneuroim.2005.03.020.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"1038_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000699","volume":"7","author":"C Simard","year":"2020","unstructured":"Simard C, Vogrig A, Joubert B, Mu\u00f1iz-Castrillo S, Picard G, Rogemond V, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e699. https:\/\/doi.org\/10.1212\/NXI.0000000000000699.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"1038_CR4","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/archneurol.2011.128","volume":"68","author":"A McKeon","year":"2011","unstructured":"McKeon A, Tracy JA, Pittock SJ, Parisi JE, Klein CJ, Lennon VA. Purkinje Cell Cytoplasmic Autoantibody Type 1 Accompaniments: The Cerebellum and Beyond. Arch Neurol. 2011;68(10):1282\u20139. https:\/\/doi.org\/10.1001\/archneurol.2011.128.","journal-title":"Arch Neurol"},{"issue":"20","key":"1038_CR5","doi-asserted-by":"publisher","first-page":"e1873","DOI":"10.1212\/WNL.0000000000008472","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, Jitprapaikulsan J, Bi H, Do Campo RV, McKeon A, Pittock SJ, et al. Amphiphysin-IgG auto-immune neuropathy: a recognizable clinicopathologic syndrome. Neurology. 2019;93(20):e1873\u201380. https:\/\/doi.org\/10.1212\/WNL.0000000000008472.","journal-title":"Neurology"},{"key":"1038_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109074","volume":"241","author":"E-C Li","year":"2022","unstructured":"Li E-C, Lai Q-L, Cai M-T, Zheng Y, Fang G-L, Fang W, et al. Kelch-like protein 11 antibody-associated paraneoplastic neurological syndrome: a state-of-the-art review. Clin Immunol. 2022;241:109074. https:\/\/doi.org\/10.1016\/j.clim.2022.109074.","journal-title":"Clin Immunol"},{"issue":"1","key":"1038_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.nrl.2016.05.010","volume":"33","author":"G Ortega Suero","year":"2018","unstructured":"Ortega Suero G, Sola-Valls N, Escudero D, Saiz A, Graus F. Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes. Neurologia (Engl Ed). 2018;33(1):18\u201327. https:\/\/doi.org\/10.1016\/j.nrl.2016.05.010.","journal-title":"Neurologia (Engl Ed)"},{"issue":"8","key":"1038_CR8","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1093\/brain\/awac088","volume":"145","author":"A Al-Diwani","year":"2022","unstructured":"Al-Diwani A, Theorell J, Damato V, Bull J, McGlashan N, Green E, et al. Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis. Brain. 2022;145(8):2742\u201354. https:\/\/doi.org\/10.1093\/brain\/awac088.","journal-title":"Brain"},{"issue":"5","key":"1038_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200015","volume":"9","author":"E Peter","year":"2022","unstructured":"Peter E, Treilleux I, Wucher V, Jougla E, Vogrig A, Pissaloux D, et al. Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e200015. https:\/\/doi.org\/10.1212\/NXI.0000000000200015.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"1038_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1260212","volume":"6","author":"C Gebauer","year":"2016","unstructured":"Gebauer C, Pignolet B, Yshii L, Maur\u00e9 E, Bauer J, Liblau R. CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model. Oncoimmunology. 2016;6(2):e1260212. https:\/\/doi.org\/10.1080\/2162402X.2016.1260212.","journal-title":"Oncoimmunology"},{"issue":"1\u20132","key":"1038_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jneuroim.2010.05.035","volume":"226","author":"MT de Graaf","year":"2010","unstructured":"de Graaf MT, de Beukelaar JWK, Haasnoot GW, Levering WHBM, Rogemond V, Didelot A, et al. HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol. 2010;226(1\u20132):147\u20139. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.05.035.","journal-title":"J Neuroimmunol"},{"key":"1038_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2017.12.012","volume":"315","author":"RP Hillary","year":"2018","unstructured":"Hillary RP, Ollila HM, Lin L, Desestret V, Rogemond V, Picard G, et al. Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. J Neuroimmunol. 2018;315:28\u201332. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.12.012.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"1038_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z, et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct Target Ther. 2024;9(1):225. https:\/\/doi.org\/10.1038\/s41392-024-01947-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1038_CR14","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1111\/jdv.18464","volume":"36","author":"YH Wu","year":"2022","unstructured":"Wu YH, Wu F, Yan GR, Zeng QY, Jia N, Zheng Z, et al. Features and clinical significance of tertiary lymphoid structure in cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2022;36(11):2043\u201350. https:\/\/doi.org\/10.1111\/jdv.18464.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1038_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143558","volume":"10","author":"P Gozzard","year":"2015","unstructured":"Gozzard P, Chapman C, Vincent A, Lang B, Maddison P. Novel humoral prognostic markers in small-cell lung carcinoma: a prospective study. PLoS ONE. 2015;10(11):e0143558. https:\/\/doi.org\/10.1371\/journal.pone.0143558.","journal-title":"PLoS ONE"},{"issue":"5","key":"1038_CR16","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/brain\/aws082","volume":"135","author":"CG Bien","year":"2012","unstructured":"Bien CG, Vincent A, Barnett MH, Becker AJ, Bl\u00fcmcke I, Graus F, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135(5):1622\u201338. https:\/\/doi.org\/10.1093\/brain\/aws082.","journal-title":"Brain"},{"issue":"2","key":"1038_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO;2-R","volume":"45","author":"B Benyahia","year":"1999","unstructured":"Benyahia B, Liblau R, Merle-B\u00e9ral H, Tourani JM, Dalmau J, Delattre JY. Cell-Mediated Autoimmunity in Paraneoplastic Neurological Syndromes with Anti-Hu Antibodies. Ann Neurol. 1999;45(2):162\u20137. https:\/\/doi.org\/10.1002\/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO;2-R","journal-title":"Ann Neurol"},{"issue":"12","key":"1038_CR18","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27384","volume":"2","author":"BS Pignolet","year":"2013","unstructured":"Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of Paraneoplastic Neurological Syndromes Associated with Anti-Hu Antibodies. Oncoimmunology. 2013;2(12):e27384. https:\/\/doi.org\/10.4161\/onci.27384.","journal-title":"Oncoimmunology"},{"issue":"1\u20132","key":"1038_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jneuroim.2008.01.007","volume":"195","author":"M de Graaf","year":"2008","unstructured":"de Graaf M, de Beukelaar J, Bergsma J, Kraan J, van den Bent M, Klimek M, et al. B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. J Neuroimmunol. 2008;195(1\u20132):164\u201370. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.01.007.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"1038_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35610-w","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Yang L, Wang G, Yuan Y, Wei N, Yang W, et al. Extensive cytokine biomarker analysis in serum of Guillain-Barr\u00e9 syndrome patients. Sci Rep. 2023;13(1):8354. https:\/\/doi.org\/10.1038\/s41598-023-35610-w.","journal-title":"Sci Rep"},{"issue":"15","key":"1038_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178602","volume":"134","author":"M Seyedsadr","year":"2024","unstructured":"Seyedsadr M, Bang MF, McCarthy EC, Zhang S, Chen H-C, Mohebbi M, et al. A pathologically expanded, clonal lineage of IL-21\u2013producing CD4+ T cells drives inflammatory neuropathy. J Clin Invest. 2024;134(15):e178602. https:\/\/doi.org\/10.1172\/JCI178602.","journal-title":"J Clin Invest"},{"issue":"6","key":"1038_CR22","first-page":"637","volume":"68","author":"G Stoll","year":"1993","unstructured":"Stoll G, Jander S, Jung S, Archelos J, Tamatani T, Miyasaka M, et al. Macrophages and endothelial cells express intercellular adhesion molecule-1 in immune-mediated demyelination but not in Wallerian degeneration of the rat peripheral nervous system. Lab Invest. 1993;68(6):637\u201344.","journal-title":"Lab Invest"},{"issue":"5","key":"1038_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00401-001-0498-0","volume":"103","author":"F Bernal","year":"2002","unstructured":"Bernal F, Graus F, Pifarr\u00e9 A, Saiz A, Benyahia B, Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol. 2002;103(5):509\u201315. https:\/\/doi.org\/10.1007\/s00401-001-0498-0.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1038_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1212\/wnl.44.1.140","volume":"44","author":"WC Jean","year":"1994","unstructured":"Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology. 1994;44(1):140\u20137. https:\/\/doi.org\/10.1212\/wnl.44.1.140.","journal-title":"Neurology"},{"issue":"6","key":"1038_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/apha.70048","volume":"241","author":"B Li","year":"2025","unstructured":"Li B, Xia M, Harkany T, Verkhratsky A. Cerebrospinal fluid enters peripheral organs by spinal nerves supporting brain-body volume transmission. Acta Physiol (Oxf). 2025;241(6):e70048. https:\/\/doi.org\/10.1111\/apha.70048.","journal-title":"Acta Physiol (Oxf)"},{"issue":"1","key":"1038_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-025-00645-w","volume":"22","author":"R Rzepli\u0144ski","year":"2025","unstructured":"Rzepli\u0144ski R, Proulx ST, Tarka S, St\u0119pie\u0144 T, Ciszek B. CSF outflow from the human spinal canal: preliminary results from an anatomical specimen-based model. Fluids Barriers CNS. 2025;22(1):32. https:\/\/doi.org\/10.1186\/s12987-025-00645-w.","journal-title":"Fluids Barriers CNS"},{"key":"1038_CR27","doi-asserted-by":"publisher","unstructured":"Li X, Wang S, Zhang D, Feng Y, Liu Y, Yu W, Li S, Cui L, Harkany T, Verkhratsky A, Xia M, Li B. Ependymocytes Control Cerebrospinal Fluid Flow to the Peripheral Organs through Periaxonal Pathway. bioRxiv October 13, 2023, p 2023.10.09.560634. https:\/\/doi.org\/10.1101\/2023.10.09.560634.","DOI":"10.1101\/2023.10.09.560634"},{"key":"1038_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1233908","volume":"14","author":"C Laaker","year":"2023","unstructured":"Laaker C, Baenen C, Kov\u00e1cs KG, Sandor M, Fabry Z. Immune cells as messengers from the CNS to the periphery: the role of the meningeal lymphatic system in immune cell migration from the CNS. Front Immunol. 2023;14:1233908. https:\/\/doi.org\/10.3389\/fimmu.2023.1233908.","journal-title":"Front Immunol"},{"key":"1038_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/antib15010008","author":"S Dimitrov","year":"2026","unstructured":"Dimitrov S, Tsalta-Mladenov M, Kabakchieva P, Georgiev T, Andonova S. Paraneoplastic neurological syndromes: advances and future perspectives in immunopathogenesis and management. Antibodies. 2026. https:\/\/doi.org\/10.3390\/antib15010008.","journal-title":"Antibodies"},{"issue":"5","key":"1038_CR30","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/biomedicines11051406","volume":"11","author":"L Marsili","year":"2023","unstructured":"Marsili L, Marcucci S, LaPorta J, Chirra M, Espay AJ, Colosimo C. Paraneoplastic neurological syndromes of the central nervous system: pathophysiology, diagnosis, and treatment. Biomedicines. 2023;11(5):1406. https:\/\/doi.org\/10.3390\/biomedicines11051406.","journal-title":"Biomedicines"},{"key":"1038_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-014-0160-0","volume":"11","author":"JE Greenlee","year":"2014","unstructured":"Greenlee JE, Clawson SA, Hill KE, Wood B, Clardy SL, Tsunoda I, et al. Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. J Neuroinflammation. 2014;11:160. https:\/\/doi.org\/10.1186\/s12974-014-0160-0.","journal-title":"J Neuroinflammation"},{"issue":"10","key":"1038_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/NEN.0b013e3181f0c82b","volume":"69","author":"JE Greenlee","year":"2010","unstructured":"Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol. 2010;69(10):997\u20131007. https:\/\/doi.org\/10.1097\/NEN.0b013e3181f0c82b.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"1038_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62380-y","volume":"16","author":"L Martin","year":"2025","unstructured":"Martin L, Stratton HJ, Salih LY, Dumaire NL, Gomez K, Do LD, et al. Anti-CV2\/CRMP5 autoantibodies as drivers of sensory neuron excitability and pain in rats. Nat Commun. 2025;16(1):7311. https:\/\/doi.org\/10.1038\/s41467-025-62380-y.","journal-title":"Nat Commun"},{"issue":"16","key":"1038_CR34","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021;96(16):754\u201366. https:\/\/doi.org\/10.1212\/WNL.0000000000011795.","journal-title":"Neurology"},{"key":"1038_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200058","author":"A Farina","year":"2023","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Ciano-Petersen NL, Vogrig A, Mu\u00f1iz-Castrillo S, Taillandier L, et al. Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/NXI.0000000000200058.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"1038_CR36","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/ana.410380117","volume":"38","author":"GT Manley","year":"1995","unstructured":"Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol. 1995;38(1):102\u201310. https:\/\/doi.org\/10.1002\/ana.410380117.","journal-title":"Ann Neurol"},{"issue":"4","key":"1038_CR37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3346\/jkms.1997.12.4.305","volume":"12","author":"JH Cho","year":"1997","unstructured":"Cho JH, Noguchi M. Expression of HuD (a paraneoplastic encephalomyelitis antigen) mRNA in lung cancer. J Korean Med Sci. 1997;12(4):305\u201310. https:\/\/doi.org\/10.3346\/jkms.1997.12.4.305.","journal-title":"J Korean Med Sci"},{"issue":"9","key":"1038_CR38","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1523\/JNEUROSCI.17-09-03024.1997","volume":"17","author":"HJ Okano","year":"1997","unstructured":"Okano HJ, Darnell RB. A hierarchy of Hu RNA binding proteins in developing and adult neurons. J Neurosci. 1997;17(9):3024\u201337. https:\/\/doi.org\/10.1523\/JNEUROSCI.17-09-03024.1997.","journal-title":"J Neurosci"},{"issue":"1","key":"1038_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/s0014-4886(03)00103-1","volume":"183","author":"KD Anderson","year":"2003","unstructured":"Anderson KD, Merhege MA, Morin M, Bolognani F, Perrone-Bizzozero NI. Increased expression and localization of the RNA-binding protein HuD and GAP-43 mRNA to cytoplasmic granules in DRG neurons during nerve regeneration. Exp Neurol. 2003;183(1):100\u20138. https:\/\/doi.org\/10.1016\/s0014-4886(03)00103-1.","journal-title":"Exp Neurol"},{"key":"1038_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.brainres.2017.01.019","volume":"1659","author":"MD Sanna","year":"2017","unstructured":"Sanna MD, Ghelardini C, Galeotti N. HuD-mediated distinct BDNF regulatory pathways promote regeneration after nerve injury. Brain Res. 2017;1659:55\u201363. https:\/\/doi.org\/10.1016\/j.brainres.2017.01.019.","journal-title":"Brain Res"},{"issue":"11","key":"1038_CR41","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1212\/wnl.41.11.1757","volume":"41","author":"J Dalmau","year":"1991","unstructured":"Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis\/sensory neuronopathy. Neurology. 1991;41(11):1757\u201364. https:\/\/doi.org\/10.1212\/wnl.41.11.1757.","journal-title":"Neurology"},{"issue":"6540","key":"1038_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/376509a0","volume":"376","author":"Y Goshima","year":"1995","unstructured":"Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM. Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature. 1995;376(6540):509\u201314. https:\/\/doi.org\/10.1038\/376509a0.","journal-title":"Nature"},{"issue":"4","key":"1038_CR43","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1523\/JNEUROSCI.5563-11.2012","volume":"32","author":"N Yamashita","year":"2012","unstructured":"Yamashita N, Ohshima T, Nakamura F, Kolattukudy P, Honnorat J, Mikoshiba K, et al. Phosphorylation of CRMP2 (collapsin response mediator protein 2) is involved in proper dendritic field organization. J Neurosci. 2012;32(4):1360\u20135. https:\/\/doi.org\/10.1523\/JNEUROSCI.5563-11.2012.","journal-title":"J Neurosci"},{"issue":"3","key":"1038_CR44","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12035-011-8166-4","volume":"43","author":"K Hensley","year":"2011","unstructured":"Hensley K, Venkova K, Christov A, Gunning W, Park J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol. 2011;43(3):180\u201391. https:\/\/doi.org\/10.1007\/s12035-011-8166-4.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"1038_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E","volume":"49","author":"Z Yu","year":"2001","unstructured":"Yu Z, Kryzer TJ, Griesmann GE, Kim K-K, Benarroch EE, Lennon VA. CRMP-5 Neuronal Autoantibody: Marker of Lung Cancer and Thymoma-Related Autoimmunity. Ann Neurol. 2001;49(2):146\u201354.\u00a0https:\/\/doi.org\/10.1002\/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E","journal-title":"Ann Neurol"},{"issue":"7","key":"1038_CR46","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/j.1460-2075.1992.tb05317.x","volume":"11","author":"B Lichte","year":"1992","unstructured":"Lichte B, Veh RW, Meyer HE, Kilimann MW. Amphiphysin, a novel protein associated with synaptic vesicles. EMBO J. 1992;11(7):2521\u201330. https:\/\/doi.org\/10.1002\/j.1460-2075.1992.tb05317.x.","journal-title":"EMBO J"},{"issue":"Pt 2","key":"1038_CR47","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/brain\/awv324","volume":"139","author":"C Werner","year":"2016","unstructured":"Werner C, Pauli M, Doose S, Weishaupt A, Haselmann H, Gr\u00fcnewald B, et al. Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain. 2016;139(Pt 2):365\u201379. https:\/\/doi.org\/10.1093\/brain\/awv324.","journal-title":"Brain"},{"issue":"1","key":"1038_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/ana.20529","volume":"58","author":"SJ Pittock","year":"2005","unstructured":"Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58(1):96\u2013107. https:\/\/doi.org\/10.1002\/ana.20529.","journal-title":"Ann Neurol"},{"issue":"5","key":"1038_CR49","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1600-0404.2011.01572.x","volume":"125","author":"O Stich","year":"2012","unstructured":"Stich O, Klages E, Bischler P, Jarius S, Rasiah C, Voltz R, et al. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes. Acta Neurol Scand. 2012;125(5):326\u201331. https:\/\/doi.org\/10.1111\/j.1600-0404.2011.01572.x.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1038_CR50","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12974-016-0737-x","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ringelstein M, Haas J, Serysheva II, Komorowski L, Fechner K, et al. Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. J Neuroinflammation. 2016;13(1):278. https:\/\/doi.org\/10.1186\/s12974-016-0737-x.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"1038_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1212\/WNL.0000000000009895","volume":"95","author":"JK Wong","year":"2020","unstructured":"Wong JK, Yu J, Patterson A, Carlson A, Wagle Shukla A. Clinical and imaging features of newly recognized Kelch-like protein 11 paraneoplastic syndrome. Neurology. 2020;95(3):134\u20135. https:\/\/doi.org\/10.1212\/WNL.0000000000009895.","journal-title":"Neurology"},{"issue":"5","key":"1038_CR52","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/ana.26050","volume":"89","author":"D Dubey","year":"2021","unstructured":"Dubey D, Kryzer T, Guo Y, Clarkson B, Cheville JC, Costello BA, et al. Leucine zipper 4 auto-antibody: a novel germ cell tumor and paraneoplastic biomarker. Ann Neurol. 2021;89(5):1001\u201310. https:\/\/doi.org\/10.1002\/ana.26050.","journal-title":"Ann Neurol"},{"issue":"1","key":"1038_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/jns.70013","volume":"30","author":"A Panrudkevich","year":"2025","unstructured":"Panrudkevich A, Jabari D, Putko B, Daley C, Lewis RA, Dubey D, et al. Paraneoplastic leucine zipper 4 IgG associated motor-predominant polyradiculoneuropathy. J Peripher Nerv Syst. 2025;30(1):e70013. https:\/\/doi.org\/10.1111\/jns.70013.","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"1038_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/ana.24872","volume":"81","author":"A Gadoth","year":"2017","unstructured":"Gadoth A, Kryzer TJ, Fryer J, McKeon A, Lennon VA, Pittock SJ. Microtubule-associated protein 1B: novel paraneoplastic biomarker. Ann Neurol. 2017;81(2):266\u201377. https:\/\/doi.org\/10.1002\/ana.24872.","journal-title":"Ann Neurol"},{"issue":"3","key":"1038_CR55","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00415-010-5776-0","volume":"258","author":"P McNamara","year":"2011","unstructured":"McNamara P, Costelloe L, Langan Y, Redmond J. Anti-Yo positive dorsal root ganglionopathy. J Neurol. 2011;258(3):519\u201320. https:\/\/doi.org\/10.1007\/s00415-010-5776-0.","journal-title":"J Neurol"},{"key":"1038_CR56","doi-asserted-by":"publisher","unstructured":"Li, Z.-C.; Cai, H.-B.; Fan, Z.-Z.; Zhai, X.-B.; Ge, Z.-M. Paraneoplastic Neurological Syndrome with Positive Anti-Hu and Anti-Yo Antibodies: A Case Report. World Journal of Clinical Cases 2022, 10 (13), 4190\u20134195. https:\/\/doi.org\/10.12998\/wjcc.v10.i13.4190.","DOI":"10.12998\/wjcc.v10.i13.4190"},{"issue":"7","key":"1038_CR57","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awp136","volume":"132","author":"J-P Camdessanch\u00e9","year":"2009","unstructured":"Camdessanch\u00e9 J-P, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case\u2013control study. Brain. 2009;132(7):1723\u201333. https:\/\/doi.org\/10.1093\/brain\/awp136.","journal-title":"Brain"},{"issue":"1","key":"1038_CR58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1055\/s-2008-1041406","volume":"7","author":"AK Asbury","year":"1987","unstructured":"Asbury AK. Sensory neuronopathy. Semin Neurol. 1987;7(1):58\u201366. https:\/\/doi.org\/10.1055\/s-2008-1041406.","journal-title":"Semin Neurol"},{"issue":"3","key":"1038_CR59","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mus.20100","volume":"30","author":"T Kuntzer","year":"2004","unstructured":"Kuntzer T, Antoine J-C, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve. 2004;30(3):255\u201368. https:\/\/doi.org\/10.1002\/mus.20100.","journal-title":"Muscle Nerve"},{"issue":"10","key":"1038_CR60","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.neurol.2023.12.012","volume":"180","author":"J-C Antoine","year":"2024","unstructured":"Antoine J-C. Inflammatory sensory neuronopathies. Rev Neurol (Paris). 2024;180(10):1037\u201346. https:\/\/doi.org\/10.1016\/j.neurol.2023.12.012.","journal-title":"Rev Neurol (Paris)"},{"issue":"12","key":"1038_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.880","volume":"7","author":"P Zis","year":"2017","unstructured":"Zis P, Hadjivassiliou M, Sarrigiannis PG, Barker ASJE, Rao DG. Rapid neurophysiological screening for sensory ganglionopathy: a novel approach. Brain Behav. 2017;7(12):e00880. https:\/\/doi.org\/10.1002\/brb3.880.","journal-title":"Brain Behav"},{"issue":"4","key":"1038_CR62","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/mus.1032","volume":"24","author":"JP Lefaucheur","year":"2001","unstructured":"Lefaucheur JP, Debray S, Jarry G. Laser evoked potentials using the Nd:YAG laser. Muscle Nerve. 2001;24(4):496\u2013501. https:\/\/doi.org\/10.1002\/mus.1032.","journal-title":"Muscle Nerve"},{"issue":"8","key":"1038_CR63","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/mus.1107","volume":"24","author":"G Lauria","year":"2001","unstructured":"Lauria G, Sghirlanzoni A, Lombardi R, Pareyson D. Epidermal nerve fiber density in sensory ganglionopathies: clinical and neurophysiologic correlations. Muscle Nerve. 2001;24(8):1034\u20139. https:\/\/doi.org\/10.1002\/mus.1107.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1038_CR64","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/ene.13608","volume":"25","author":"V Provitera","year":"2018","unstructured":"Provitera V, Gibbons CH, Wendelschafer-Crabb G, Donadio V, Vitale DF, Loavenbruck A, et al. The role of skin biopsy in differentiating small-fiber neuropathy from ganglionopathy. Eur J Neurol. 2018;25(6):848\u201353. https:\/\/doi.org\/10.1111\/ene.13608.","journal-title":"Eur J Neurol"},{"issue":"3","key":"1038_CR65","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12330","volume":"24","author":"ARM Martinez","year":"2019","unstructured":"Martinez ARM, Martins MP, Martins CR, Faber I, de Rezende TJR, Nucci A, et al. Sensory ataxia rating scale: development and validation of a functional scale for patients with sensory neuronopathies. J Peripher Nerv Syst. 2019;24(3):242\u20136. https:\/\/doi.org\/10.1111\/jns.12330.","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"1038_CR66","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","volume":"13","author":"V Chaudhry","year":"2008","unstructured":"Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst. 2008;13(4):275\u201382. https:\/\/doi.org\/10.1111\/j.1529-8027.2008.00193.x.","journal-title":"J Peripher Nerv Syst"},{"issue":"17","key":"1038_CR67","doi-asserted-by":"publisher","first-page":"7603","DOI":"10.7314\/APJCP.2015.16.17.7603","volume":"16","author":"A Shahriari-Ahmadi","year":"2015","unstructured":"Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M. Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran. Asian Pac J Cancer Prev. 2015;16(17):7603\u20136. https:\/\/doi.org\/10.7314\/APJCP.2015.16.17.7603.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"1038_CR68","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772\u201381. https:\/\/doi.org\/10.1002\/ana.24951.","journal-title":"Ann Neurol"},{"key":"1038_CR69","doi-asserted-by":"publisher","unstructured":"Camdessanch\u00e9 J-P, Jousserand G, Franques J, Pouget J, Delmont E, Cr\u00e9ange A, Kuntzer T, Maisonobe T, Abba K, Antoine J-C, French CIDP study group. A Clinical Pattern-Based Etiological Diagnostic Strategy for Sensory Neuronopathies: A French Collaborative Study. J Peripher Nerv Syst 2012, 17 (3), 331\u2013340. https:\/\/doi.org\/10.1111\/j.1529-8027.2012.00411.x.","DOI":"10.1111\/j.1529-8027.2012.00411.x"},{"issue":"2","key":"1038_CR70","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1212\/WNL.0000000000004803","volume":"90","author":"D Dubey","year":"2018","unstructured":"Dubey D, Lennon VA, Gadoth A, Pittock SJ, Flanagan EP, Schmeling JE, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90(2):e103\u201310. https:\/\/doi.org\/10.1212\/WNL.0000000000004803.","journal-title":"Neurology"},{"issue":"7_Supplement_1","key":"1038_CR71","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211172","volume":"104","author":"A Panrudkevich","year":"2025","unstructured":"Panrudkevich A, Jabari D, Putko B, Daley C, Lewis R, Dubey D, et al. Paraneoplastic leucine zipper 4 auto-antibody associated motor-predominant polyradiculoneuropathy (P4-8.008). Neurology. 2025;104(7_Supplement_1):3689. https:\/\/doi.org\/10.1212\/WNL.0000000000211172.","journal-title":"Neurology"},{"key":"1038_CR72","doi-asserted-by":"publisher","unstructured":"Cluse F, Do LD, Bernard E, Rogemond V, Closs S, Rumnici E, Quadrio I, Benaiteau M, Honnorat J Paraneoplastic Brachial Amyotrophic Diplegia With Favorable Outcome and Anti-Ank3 Antibodies. Neurology: Neuroimmunology and NeuroInflammation 2025, 12 (6). https:\/\/doi.org\/10.1212\/NXI.0000000000200488.","DOI":"10.1212\/NXI.0000000000200488"},{"issue":"4","key":"1038_CR73","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1212\/01.CON.0000403798.87740.cc","volume":"17","author":"DI Rubin","year":"2011","unstructured":"Rubin DI. Acute and chronic polyradiculopathies. Continuum (Minneap Minn). 2011;17(4):831\u201354. https:\/\/doi.org\/10.1212\/01.CON.0000403798.87740.cc.","journal-title":"Continuum (Minneap Minn)"},{"issue":"7","key":"1038_CR74","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/jnnp.54.7.610","volume":"54","author":"J Julien","year":"1991","unstructured":"Julien J, Vital C, Rivel J, de Mascarel A, Lagueny A, Ferrer X, et al. Primary meningeal B lymphoma presenting as a subacute ascending polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 1991;54(7):610\u20133. https:\/\/doi.org\/10.1136\/jnnp.54.7.610.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1038_CR75","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10072-019-04078-w","volume":"41","author":"K Shindo","year":"2020","unstructured":"Shindo K, Tsuchiya M, Koh K, Nagasaka T, Takiyama Y. Paraneoplastic sensorimotor neuropathy associated with mediastinal germ cell tumor: favorable outcome after high-dose intravenous immunoglobulin therapy. Neurol Sci. 2020;41(3):723\u20135. https:\/\/doi.org\/10.1007\/s10072-019-04078-w.","journal-title":"Neurol Sci"},{"key":"1038_CR76","doi-asserted-by":"publisher","unstructured":"Amano, R.; Kim, Y.-J.; Yoshida, T.; Hara, M.; Nakajima, H.; Ohtsuka, T.; Yazawa, M. Case Report: Reversible Brain Atrophy with Low Titer Anti-amphiphysin Antibodies Related to Gastric Adenocarcinoma. Frontiers in Neurology 2023, 14. https:\/\/doi.org\/10.3389\/fneur.2023.1211814.","DOI":"10.3389\/fneur.2023.1211814"},{"issue":"2","key":"1038_CR77","first-page":"197","volume":"58","author":"I Casas Parera","year":"1998","unstructured":"Casas Parera I, Fischman D, Paz L, Lehkuniec E, Muchnik S. Paraneoplastic neuropathy with positive anti-Hu. Medicina (B Aires). 1998;58(2):197\u2013201.","journal-title":"Medicina (B Aires)"},{"key":"1038_CR78","doi-asserted-by":"publisher","unstructured":"Camdessanch\u00e9 J-P, Antoine J-C, Honnorat J, Vial C, Petiot P, Convers P, Michel D Paraneoplastic Peripheral Neuropathy Associated with Anti-Hu Antibodies. A Clinical and Electrophysiological Study of 20 Patients. Brain 2002, 125 (Pt 1), 166\u2013175. https:\/\/doi.org\/10.1093\/brain\/awf006.","DOI":"10.1093\/brain\/awf006"},{"key":"1038_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-253686","author":"M Lizwan","year":"2023","unstructured":"Lizwan M, Lin SZZ, Sonu SK. Rare case of anti-CV2 paraneoplastic polyneuropathy associated with lung adenocarcinoma. BMJ Case Rep. 2023. https:\/\/doi.org\/10.1136\/bcr-2022-253686.","journal-title":"BMJ Case Rep"},{"issue":"5","key":"1038_CR80","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1971400920919689","volume":"33","author":"AA Madhavan","year":"2020","unstructured":"Madhavan AA, Guerin JB, Eckel LJ, Lehman VT, Carr CM. Dorsal cauda equina nerve root enhancement on magnetic resonance imaging due to ANNA-1-associated paraneoplastic polyneuropathy. Neuroradiol J. 2020;33(5):443\u20137. https:\/\/doi.org\/10.1177\/1971400920919689.","journal-title":"Neuroradiol J"},{"issue":"2","key":"1038_CR81","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/1531-8249(20010201)49:2<214::AID-ANA41>3.0.CO;2-W","volume":"49","author":"J-C Antoine","year":"2001","unstructured":"Antoine J-C, Honnorat J, Camdessanch\u00e9 J-P, Magistris M, Absi L, Mosnier J-F, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001;49(2):214\u201321.\u00a0https:\/\/doi.org\/10.1002\/1531-8249(20010201)49:2<214::AID-ANA41>3.0.CO;2-W","journal-title":"Ann Neurol"},{"issue":"2","key":"1038_CR82","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00415-018-9143-x","volume":"266","author":"A Vogrig","year":"2019","unstructured":"Vogrig A, Joubert B, Maureille A, Thomas L, Bernard E, Streichenberger N, et al. Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. J Neurol. 2019;266(2):398\u2013410. https:\/\/doi.org\/10.1007\/s00415-018-9143-x.","journal-title":"J Neurol"},{"issue":"12","key":"1038_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11121577","volume":"11","author":"Y Guo","year":"2021","unstructured":"Guo Y, Cai M-T, Lai Q-L, Zheng Y, Shen C-H, Zhang Y-X. Anti-Ma2 antibody-associated paraneoplastic neurological syndromes: a pilot study. Brain Sci. 2021;11(12):1577. https:\/\/doi.org\/10.3390\/brainsci11121577.","journal-title":"Brain Sci"},{"issue":"6","key":"1038_CR84","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1007\/s00415-024-12278-4","volume":"271","author":"M Villagr\u00e1n-Garc\u00eda","year":"2024","unstructured":"Villagr\u00e1n-Garc\u00eda M, Farina A, Arzalluz-Luque J, Campetella L, Mu\u00f1iz-Castrillo S, Benaiteau M, et al. Dysautonomia in anti-Hu paraneoplastic neurological syndromes. J Neurol. 2024;271(6):3359\u201369. https:\/\/doi.org\/10.1007\/s00415-024-12278-4.","journal-title":"J Neurol"},{"issue":"20","key":"1038_CR85","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1212\/01.wnl.0000312280.44805.5d","volume":"70","author":"S Vernino","year":"2008","unstructured":"Vernino S, Sandroni P, Singer W, Low PA. Invited Article: Autonomic Ganglia: Target and Novel Therapeutic Tool. Neurology. 2008;70(20):1926\u201332. https:\/\/doi.org\/10.1212\/01.wnl.0000312280.44805.5d.","journal-title":"Neurology"},{"issue":"Pt 6","key":"1038_CR86","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","volume":"124","author":"F Graus","year":"2001","unstructured":"Graus F, Keime-Guibert F, Re\u00f1e R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-Associated Paraneoplastic Encephalomyelitis: Analysis of 200 Patients. Brain. 2001;124(Pt 6):1138\u201348. https:\/\/doi.org\/10.1093\/brain\/124.6.1138.","journal-title":"Brain"},{"issue":"1","key":"1038_CR87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.clinph.2004.07.012","volume":"116","author":"SJ Oh","year":"2005","unstructured":"Oh SJ, G\u00fcrtekin Y, Dropcho EJ, King P, Claussen GC. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol. 2005;116(1):28\u201334. https:\/\/doi.org\/10.1016\/j.clinph.2004.07.012.","journal-title":"Clin Neurophysiol"},{"issue":"2","key":"1038_CR88","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00005792-199203000-00001","volume":"71","author":"J Dalmau","year":"1992","unstructured":"Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis\/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore). 1992;71(2):59\u201372. https:\/\/doi.org\/10.1097\/00005792-199203000-00001.","journal-title":"Medicine (Baltimore)"},{"key":"1038_CR89","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/B978-0-444-52902-2.00041-2","volume":"115","author":"H Koike","year":"2013","unstructured":"Koike H, Sobue G. Paraneoplastic neuropathy. Handb Clin Neurol. 2013;115:713\u201326. https:\/\/doi.org\/10.1016\/B978-0-444-52902-2.00041-2.","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"1038_CR90","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002299","volume":"95","author":"G Di Lorenzo","year":"2016","unstructured":"Di Lorenzo G, Bracarda S, Gasparro D, Gernone A, Messina C, Zagonel V, et al. Lack of cumulative toxicity associated with cabazitaxel use in prostate cancer. Medicine (Baltimore). 2016;95(2):e2299. https:\/\/doi.org\/10.1097\/MD.0000000000002299.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1038_CR91","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/j.clgc.2015.01.010","volume":"13","author":"A Omlin","year":"2015","unstructured":"Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono JS, Shen L, et al. Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel. Clin Genitourin Cancer. 2015;13(4):e205\u20138. https:\/\/doi.org\/10.1016\/j.clgc.2015.01.010.","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"1038_CR92","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1200\/JCO.1996.14.11.2923","volume":"14","author":"C Bokemeyer","year":"1996","unstructured":"Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996;14(11):2923\u201332. https:\/\/doi.org\/10.1200\/JCO.1996.14.11.2923.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1038_CR93","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0883073813491829","volume":"29","author":"P Jain","year":"2014","unstructured":"Jain P, Gulati S, Seth R, Bakhshi S, Toteja GS, Pandey RM. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol. 2014;29(7):932\u20137. https:\/\/doi.org\/10.1177\/0883073813491829.","journal-title":"J Child Neurol"},{"issue":"19","key":"1038_CR94","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.04.7779.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1038_CR95","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/jnnp.31.6.543","volume":"31","author":"PM Fullerton","year":"1968","unstructured":"Fullerton PM, O\u2019Sullivan DJ. Thalidomide Neuropathy: A Clinical Electrophysiological, and Histological Follow-up Study. J Neurol Neurosurg Psychiatry. 1968;31(6):543\u201351. https:\/\/doi.org\/10.1136\/jnnp.31.6.543.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1038_CR96","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1212\/01.wnl.0000037480.59194.85","volume":"59","author":"V Chaudhry","year":"2002","unstructured":"Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O\u2019Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology. 2002;59(12):1872\u20135. https:\/\/doi.org\/10.1212\/01.wnl.0000037480.59194.85.","journal-title":"Neurology"},{"issue":"1","key":"1038_CR97","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/jnnp.2008.159483","volume":"81","author":"D Psimaras","year":"2010","unstructured":"Psimaras D, Carpentier AF, Rossi C. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry. 2010;81(1):42\u20135. https:\/\/doi.org\/10.1136\/jnnp.2008.159483.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1038_CR98","doi-asserted-by":"publisher","unstructured":"Shah S, Vazquez Do Campo R, Kumar N, McKeon A, Flanagan EP, Klein C, Pittock SJ, Dubey D Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments. Neurology 2021, 96 (4), E632\u2013E639. https:\/\/doi.org\/10.1212\/WNL.0000000000011218.","DOI":"10.1212\/WNL.0000000000011218"},{"issue":"4","key":"1038_CR99","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, Antoine J-CG, Desestret V, Dubey D, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014. https:\/\/doi.org\/10.1212\/NXI.0000000000001014.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"1038_CR100","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/rheumatology\/key451","volume":"58","author":"M Infantino","year":"2019","unstructured":"Infantino M, Tampoia M, Fabris M, Alessio MG, Previtali G, Pesce G, et al. Combining immunofluorescence with immunoblot assay improves the specificity of auto-antibody testing for myositis. Rheumatology (Oxford). 2019;58(7):1239\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/key451.","journal-title":"Rheumatology (Oxford)"},{"key":"1038_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066002","author":"TW Eichler","year":"2013","unstructured":"Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A, et al. CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0066002.","journal-title":"PLoS ONE"},{"issue":"2","key":"1038_CR102","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00262-010-0943-9","volume":"60","author":"C Totland","year":"2010","unstructured":"Totland C, Aarskog NK, Eichler TW, Haugen M, N\u00f8stbakken JK, Monstad SE, et al. CDR2 antigen and Yo antibodies. Cancer Immunol Immunother. 2010;60(2):283\u20139. https:\/\/doi.org\/10.1007\/s00262-010-0943-9.","journal-title":"Cancer Immunol Immunother"},{"key":"1038_CR103","doi-asserted-by":"publisher","unstructured":"D\u00e9chelotte B, Mu\u00f1iz-Castrillo S, Joubert B, Vogrig A, Picard G, Rogemond V, Pinto A-L, Lombard C Desestret V, Fabien N, Honnorat J Diagnostic Yield of Commercial Immunodots to Diagnose Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and NeuroInflammation 2020, 7 (3). https:\/\/doi.org\/10.1212\/NXI.0000000000000701.","DOI":"10.1212\/NXI.0000000000000701"},{"issue":"2","key":"1038_CR104","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207982","volume":"102","author":"A Granger","year":"2024","unstructured":"Granger A, Rajnauth T, Lahoria R, Dubey D, Mills J, Mauermann ML, et al. Clinicopathologic findings in patients with paraneoplastic neuropathies and antibodies strongly associated with cancer. Neurology. 2024;102(2):e207982. https:\/\/doi.org\/10.1212\/WNL.0000000000207982.","journal-title":"Neurology"},{"issue":"4","key":"1038_CR105","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1212\/wnl.49.4.1156","volume":"49","author":"J Wanschitz","year":"1997","unstructured":"Wanschitz J, Hainfellner JA, Kristoferitsch W, Drlicek M, Budka H. Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study. Neurology. 1997;49(4):1156\u20139. https:\/\/doi.org\/10.1212\/wnl.49.4.1156.","journal-title":"Neurology"},{"issue":"2","key":"1038_CR106","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1212\/wnl.40.2.219","volume":"40","author":"F Graus","year":"1990","unstructured":"Graus F, Ribalta T, Campo E, Monforte R, Urbano A, Rozman C. Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis. Neurology. 1990;40(2):219\u201322. https:\/\/doi.org\/10.1212\/wnl.40.2.219.","journal-title":"Neurology"},{"key":"1038_CR107","doi-asserted-by":"publisher","unstructured":"Titulaer, M. J.; Soffietti, R.; Dalmau, J.; Gilhus, N. E.; Giometto, B.; Graus, F.; Grisold, W.; Honnorat, J.; Sillevis Smitt, P. a. E.; Tanasescu, R.; Vedeler, C. A.; Voltz, R.; Verschuuren, J. J. G. M.; European Federation of Neurological Societies. Screening for Tumours in Paraneoplastic Syndromes: Report of an EFNS Task Force. Eur J Neurol 2011, 18 (1), 19-e3. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03220.x.","DOI":"10.1111\/j.1468-1331.2010.03220.x"},{"issue":"5","key":"1038_CR108","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.molonc.2014.10.004","volume":"9","author":"DF Hayes","year":"2015","unstructured":"Hayes DF. Biomarker validation and testing. Mol Oncol. 2015;9(5):960\u20136. https:\/\/doi.org\/10.1016\/j.molonc.2014.10.004.","journal-title":"Mol Oncol"},{"key":"1038_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577972","volume":"372","author":"L Campetella","year":"2022","unstructured":"Campetella L, Papi C, Sabatelli E, Marini S, Iorio R. Real-world application of the updated diagnostic criteria for paraneoplastic neurological syndromes. J Neuroimmunol. 2022;372:577972. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577972.","journal-title":"J Neuroimmunol"},{"issue":"24","key":"1038_CR110","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1212\/WNL.0000000000001694","volume":"84","author":"S Baiardi","year":"2015","unstructured":"Baiardi S, Provini F, Avoni P, Pasquinelli M, Liguori R. Immunotherapy of oneiric stupor in Morvan syndrome: efficacy documented by actigraphy. Neurology. 2015;84(24):2457\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000001694.","journal-title":"Neurology"},{"issue":"2","key":"1038_CR111","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ana.23577","volume":"72","author":"SR Irani","year":"2012","unstructured":"Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241\u201355. https:\/\/doi.org\/10.1002\/ana.23577.","journal-title":"Ann Neurol"},{"issue":"4","key":"1038_CR112","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00415-019-09686-2","volume":"267","author":"M Boyko","year":"2020","unstructured":"Boyko M, Au KLK, Casault C, de Robles P, Pfeffer G. Systematic review of the clinical spectrum of CASPR2 antibody syndrome. J Neurol. 2020;267(4):1137\u201346. https:\/\/doi.org\/10.1007\/s00415-019-09686-2.","journal-title":"J Neurol"},{"issue":"12","key":"1038_CR113","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJ. Lambert\u2013Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098\u2013107. https:\/\/doi.org\/10.1016\/S1474-4422(11)70245-9.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1038_CR114","first-page":"419","volume":"62","author":"S Suzuki","year":"2010","unstructured":"Suzuki S. Lambert-Eaton myasthenic syndrome (LEMS). Brain Nerve. 2010;62(4):419\u201326.","journal-title":"Brain Nerve"},{"key":"1038_CR115","doi-asserted-by":"publisher","unstructured":"B, G.; R, V.; E, L.-P.; W, G.; C, V. Treatment for Paraneoplastic Neuropathies. The Cochrane database of systematic reviews 2012, 12 (12), CD007625. https:\/\/doi.org\/10.1002\/14651858.CD007625.pub2.","DOI":"10.1002\/14651858.CD007625.pub2"},{"key":"1038_CR116","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jns.2015.12.044","volume":"361","author":"J-C Antoine","year":"2016","unstructured":"Antoine J-C, Robert-Varvat F, Maisonobe T, Cr\u00e9ange A, Franques J, Mathis S, et al. Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies. J Neurol Sci. 2016;361:187\u201391. https:\/\/doi.org\/10.1016\/j.jns.2015.12.044.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1038_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0821-8","volume":"7","author":"G Manson","year":"2019","unstructured":"Manson G, Maria ATJ, Poizeau F, Danlos F-X, Kostine M, Brosseau S, et al. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J Immunother Cancer. 2019;7(1):337. https:\/\/doi.org\/10.1186\/s40425-019-0821-8.","journal-title":"J Immunother Cancer"},{"issue":"17","key":"1038_CR118","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","volume":"95","author":"E Sechi","year":"2020","unstructured":"Sechi E, Markovic SN, McKeon A, Dubey D, Liewluck T, Lennon VA, et al. Neurologic autoimmunity and immune checkpoint inhibitors. Neurology. 2020;95(17):e2442\u201352. https:\/\/doi.org\/10.1212\/WNL.0000000000010632.","journal-title":"Neurology"},{"issue":"4","key":"1038_CR119","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","volume":"68","author":"F Keime-Guibert","year":"2000","unstructured":"Keime-Guibert F, Graus F, Fleury A, Ren\u00e9 R, Honnorat J, Broet P, et al. Treatment of Paraneoplastic Neurological Syndromes with Antineuronal Antibodies (Anti-Hu, Anti-Yo) with a Combination of Immunoglobulins, Cyclophosphamide, and Methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68(4):479\u201382. https:\/\/doi.org\/10.1136\/jnnp.68.4.479.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1038_CR120","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/jnnp-2017-316904","volume":"89","author":"G Berzero","year":"2018","unstructured":"Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, et al. Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. J Neurol Neurosurg Psychiatry. 2018;89(7):789\u201392. https:\/\/doi.org\/10.1136\/jnnp-2017-316904.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1038_CR121","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/jnnp-2017-316904","volume":"89","author":"G Berzero","year":"2018","unstructured":"Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, et al. Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. J Neurol Neurosurg Psychiatry. 2018;89(7):789\u201392. https:\/\/doi.org\/10.1136\/jnnp-2017-316904.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1038_CR122","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00415-005-0882-0","volume":"253","author":"S Shams\u2019ili","year":"2006","unstructured":"Shams\u2019ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van \u2019t Veer M, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253(1):16\u201320. https:\/\/doi.org\/10.1007\/s00415-005-0882-0.","journal-title":"J Neurol"},{"issue":"36","key":"1038_CR123","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1038_CR124","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(4):387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"1038_CR125","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41582-024-01001-6","volume":"20","author":"M O\u2019Hare","year":"2024","unstructured":"O\u2019Hare M, Guidon AC. Peripheral nervous system immune-related adverse events due to checkpoint inhibition. Nat Rev Neurol. 2024;20(9):509\u201325. https:\/\/doi.org\/10.1038\/s41582-024-01001-6.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"1038_CR126","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol. 2020;87(5):659\u201369. https:\/\/doi.org\/10.1002\/ana.25708.","journal-title":"Ann Neurol"},{"issue":"1","key":"1038_CR127","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/neuonc\/nou126","volume":"17","author":"AH de Jongste","year":"2015","unstructured":"de Jongste AH, van Gelder T, Bromberg JE, de Graaf MT, Gratama JW, Schreurs MW, et al. A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neuro Oncol. 2015;17(1):145\u201350. https:\/\/doi.org\/10.1093\/neuonc\/nou126.","journal-title":"Neuro Oncol"},{"issue":"9","key":"1038_CR128","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/archneurol.2012.595","volume":"69","author":"D Orange","year":"2012","unstructured":"Orange D, Frank M, Tian S, Dousmanis A, Marmur R, Buckley N, et al. Cellular Immune Suppression in Paraneoplastic Neurologic Syndromes Targeting Intracellular Antigens. Arch Neurol. 2012;69(9):1132\u201340. https:\/\/doi.org\/10.1001\/archneurol.2012.595.","journal-title":"Arch Neurol"},{"issue":"1","key":"1038_CR129","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab145","volume":"3","author":"AEM Bastiaansen","year":"2021","unstructured":"Bastiaansen AEM, de Jongste AHC, de Bruijn MAAM, Crijnen YS, Schreurs MWJ, Verbeek MM, et al. Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neurooncol Adv. 2021;3(1):vdab145. https:\/\/doi.org\/10.1093\/noajnl\/vdab145.","journal-title":"Neurooncol Adv"},{"issue":"1","key":"1038_CR130","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"key":"1038_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604174","author":"NA Chinas","year":"2025","unstructured":"Chinas NA, Alexopoulos H. CAR T-cells meet auto-immune neurological diseases: a new dawn for therapy. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1604174.","journal-title":"Front Immunol"},{"key":"1038_CR132","doi-asserted-by":"crossref","unstructured":"CAR-T cell therapy for cancer: current challenges and future directions | Signal Transduction and Targeted Therapy. https:\/\/www.nature.com\/articles\/s41392-025-02269-w (accessed 2026\u201308\u201311).","DOI":"10.1038\/s41392-026-02873-4"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01038-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:08:47Z","timestamp":1791569327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01038-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":132,"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01038-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marco Luigetti is an Editorial Board member of\n                      Neurology and Therapy\n                      . Marco Luigetti was not involved in the selection of peer reviewers or in any subsequent editorial decisions concerning this manuscript. Giovanni Siconolfi, Francesca Vitali, Maria Ausilia Sciarrone, Francesca Alfano, and Benjamin Mathews Varghese have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}